SARS-CoV-2 antibody positive and negative plasma used to contrive DBS specimens are described in Table 3 . SARS-CoV-2 antibody positive plasma was collected from COVID-19 convalescent donors at Mount Sinai Hospital (Toronto, Canada). Plasma was tested for SARS-CoV-2 antibodies using the Platelia SARS-CoV-2 Total Ab (Bio-Rad, Hercules, California) or Anti-SARS-CoV-2 ELISA IgG (EUROIMMUN, Lübeck, Germany) kits. SARS-CoV-2 negative plasma was collected from healthy donors within the National Microbiology Laboratory (Winnipeg, Canada). To prepare plasma, blood was collected in EDTA Vacutainer tubes (Beckton Dickinson, Franklin Lates, NJ) and centrifuged at 1,500 RPM for 7 minutes. Plasma was tested using the Platelia SARS-CoV-2 Total Ab (Bio-Rad) or Anti-SARS-CoV-2 ELISA IgG (EUROIMMUN, Lübeck, Germany) kits to verify donors were negative for SARS-CoV-2 antibodies. All assays were performed according to the manufacturer’s instructions.
Anti sars cov 2 elisa igg
Manufactured by EUROIMMUN
Sourced in Germany
The Anti-SARS-CoV-2 ELISA IgG is a laboratory equipment product developed by EUROIMMUN. It is an enzyme-linked immunosorbent assay (ELISA) used for the detection of IgG antibodies against the SARS-CoV-2 virus, the causative agent of COVID-19.
Automatically generated - may contain errors
Lab products found in correlation
Anti sars cov 2 elisa iga, by EUROIMMUN (6 mentions)
Elecsys anti sars cov 2, by Roche (4 mentions)
Anti sars cov 2 ncp elisa igg, by EUROIMMUN (4 mentions)
Cell counting kit 8 (cck8), by Dojindo Laboratories (3 mentions)
Platelia sars cov 2 total ab, by Bio-Rad (3 mentions)
Liaison sars cov 2 s1 s2 igg, by DiaSorin (3 mentions)
Ds2 elisa system, by Dynex (3 mentions)
Eti max 3000, by DiaSorin (2 mentions)
Liaison xl, by DiaSorin (2 mentions)
Architect sars cov 2 igg, by Abbott (2 mentions)
Quantivac igg, by EUROIMMUN (1 mentions)
Sars cov 2 igg assay, by Abbott (1 mentions)
Bioplex 2200 sars cov 2 igg panel, by Bio-Rad (1 mentions)
Sars cov 2 igg, by Abbott (1 mentions)
Eurolabworkstation elisa, by EUROIMMUN (1 mentions)
Anti sars cov 2 ncp elisa, by EUROIMMUN (1 mentions)
Cobas e801, by Roche (1 mentions)
Architect i2000, by Abbott (1 mentions)
Cobas 8000 c502, by Roche (1 mentions)
Edta vacutainer tube, by BD (1 mentions)
48 protocols using anti sars cov 2 elisa igg
1
Contrivance of SARS-CoV-2 Antibody DBS Specimens
2
EUROIMMUN Anti-SARS-CoV-2 ELISA IgG
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The EUROIMMUN Anti-SARS-CoV–2 ELISA IgG (Euroimmun, Luebeck, Germany) is an enzyme-linked immunosorbent assay that provides semi-quantitative in vitro determination of human IgG against recombinant S1 domain of the SARS-CoV–2 spike protein. Results are evaluated semi-quantitatively by calculation of a ratio of the extinction of the control or patient sample over the extinction of the calibrator. This ratio is interpreted as follows: <0.8 negative, ≥0.8 to <1.1 borderline, and ≥1.1 positive.
3
Detecting SARS-CoV-2 Antibodies using Euroimmun ELISA
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
To detect antibodies, we used the Euroimmun Anti‐SARS‐CoV‐2 ELISA (IgG), which was manufactured by Euroimmun Medizinische Labordiagnostika AG, Lübeck, Germany. The break‐off microplate wells were covered with the antigen, a recombinant structural spike 1 (S1) protein of SARS‐CoV‐2 expressed in HEK293 [35 (link)]. First, the diluted patient samples were incubated in the wells which lead to specific IgG antibodies binding to the antigens. In order to detect the bound antibodies, an enzyme‐labelled anti‐human IgG antibody detected antigen‐antibody complexes and catalyzed a color reaction. By calculating the extinction of the sample over the extinction of the calibrator, the results could be evaluated semiquantitatively. A ratio below 0.8 was considered a negative result. A ratio between 0.8 and 1.1 was considered a borderline result. A ratio above 1.1 was considered a positive result [36 ].
4
Euroimmun ELISA for SARS-CoV-2 IgG Detection
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The Euroimmun Anti-SARS-CoV-2 ELISA IgG (Euroimmun IgG) and the Euroimmun Anti-SARS-CoV-2 QuantiVac ELISA IgG (Euroimmun QuantiVac IgG) (Euroimmun, Lübeck, Germany) were performed on serum samples according to the manufacturer's instructions for the ELISA automated system ETI-MAX 3000 (DiaSorin, Saluggia, Italy). The microplate wells are coated with recombinant S1 structural protein. Euroimmun IgG results are evaluated semi-quantitatively by calculation of the ratio of the samples’ extinction value over the calibrator's extinction. The ratio interpretation was as follows: < 0.8 = negative, ≥ 0.8 to < 1.1 = borderline, ≥ 1.1 = positive. Euroimmun QuantiVac IgG is a specific ELISA for the quantitative detection of anti-SARS-CoV-2 IgG by means of a 6-point calibration curve. Euroimmun recommends interpreting results as follows: <8 Ratio Unit/mL (RU/mL) = negative, ≥8 to <11 RU/mL borderline, ≥11 RU/mL positive. Borderline data for both tests were considered as positive for statistical analyses.
5
SARS-CoV-2 IgG Antibody Detection
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
To exclude healthy controls with a previous SARS-CoV-2 infection, we tested the subjects for SARS-CoV-2-specific IgG antibodies by performing the Euroimmun anti-SARS-CoV-2 ELISA (IgG) (EUROIMMUN, Lübeck, Germany) (Table S2
6
Serological Evaluation of SARS-CoV-2 Antibodies
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Blood samples were collected at the CHU Saint-Pierre, and the sera were tested for SARS-CoV-2-specific immunoglobulin G (IgG) using the Euroimmun Anti-SARS-CoV-2 ELISA IgG (Euroimmun, Luebeck, Germany) according to the manufacturer’s instructions for the enzyme-linked immunosorbent assay (ELISA) automated system ETI-MAX 3000 (DiaSorin, Saluggia, Italy). The Euroimmun Anti-SARS-CoV-2 ELISA IgG uses microplate wells that are coated with the SARS-CoV-2 recombinant S1 structural protein, and the results are evaluated semi-quantitatively by calculation of a ratio of the extinction of samples over the extinction of the calibrator. This test demonstrated excellent sensitivity and specificity for detection of IgG antibodies from samples collected after COVID-19 diagnosis by polymerase chain reaction (PCR) [14 (link)]. The ratio interpretation was as follows: < 0.8: negative, ≥ 0.8 to < 1.1 borderline, ≥ 1.1 = positive.
Each enrolment included a questionnaire on age, sex, medical background, contact with PCR-positive individuals, place of work, school, and kindergarten frequentation. Symptoms compatible with COVID-19 since March 2020 and up to 15 days before the serological test were also recorded. Each participant was contacted by phone to be informed of their results and eventually complete any missing information. A retrospective review of medical files was also made when necessary.
Each enrolment included a questionnaire on age, sex, medical background, contact with PCR-positive individuals, place of work, school, and kindergarten frequentation. Symptoms compatible with COVID-19 since March 2020 and up to 15 days before the serological test were also recorded. Each participant was contacted by phone to be informed of their results and eventually complete any missing information. A retrospective review of medical files was also made when necessary.
7
SARS-CoV-2 Antibody Detection Assays
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Anti-nucleocapsid (N) IgG was determined using Abbott SARS-CoV-2 IgG assay (Abbott, Abbott Park, Illinois, U.S.A). Anti-S1 IgG was determined using the Euroimmun anti-SARS-CoV-2 ELISA (IgG) (Euroimmun, Lubeck, Germany). The Euroimmun anti-S1 IgG assay is a semi-quantitative assay by calculating the ratio of the extinction coefficient of patient's serum over the extinction coefficient of the calibrator.
8
SARS-CoV-2 Seroprevalence Among Hospital Staff
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
From April 9 to May 30 of 2020, SARS-CoV–2 seroprevalence of CHUSJ professionals was evaluated. To this end, 1027 HCW were tested for the presence of anti-SARS-CoV–2 antibodies. Among these professionals, 720 were women and 307 men, with an average age of 40 and 33 years-old, respectively. The studied population was distributed by the following hospital departments: Emergency, Infectious Disease, Intensive Care, Clinical Pathology, Surgery, Ophthalmology, and Nephrology. Detection of anti-SARS-CoV–2 antibodies was performed using the following immunoassays: Euroimmun Anti-SARS-CoV–2 ELISA IgG (Euroimmun, Luebeck, Germany) (n = 519); Abbott SARS-CoV–2 IgG (Abbott Laboratories, Chicago, Illinois, EUA) (n = 455), and Elecsys Anti-SARS-CoV–2 Total (Roche Diagnostics, Basel, Switzerland) (n = 53). The BioPlex 2200 SARS-CoV–2 IgG Panel (BIO-RAD, Hercules, California, USA) was used as an alternative immunoassay for positive results confirmation. All tests were performed according to the manufacturer's instructions.
9
SARS-CoV-2 Antibody Detection by ELISA
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
To evaluate the antibody response, the levels of total IgG in patients’ sera were semi-quantified by ELISA (cat No. WS-1096, WANTAI SARS-CoV-2 Ab ELISA, China) through the use of a Triturus ELISA processor, following manufacturer’s instructions. WANTAI SARS-CoV-2 Ab ELISA is a two-step incubation antigen “sandwich” enzyme immunoassay kit, which uses polystyrene microwell strips pre-coated with recombinant SARS-CoV-2 antigen. The results had previously been verified with another ELISA kit (Anti-SARS-CoV-2 ELISA IgG, Euroimmun, Germany), and the ELISA was done in accordance with the manufacturer’s instructions.
10
SARS-CoV-2 Antibody Assay Comparison
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Serum samples were routinely analysed for specific IgG antibodies against SARS-CoV-2 with one of three assays according to manufacturers' protocols. The LIAISON ® SARS-CoV-2 S1/S2 IgG (DiaSorin, Saluggia, Italy) uses chemiluminescence immunoassay technology for the determination of anti-S1 and anti-S2 specific IgG antibodies. The anti-SARS-CoV-2 ELISA (IgG) (EuroImmun, Lubeck, Germany) detects structural proteins, and the EDI™ Novel Coronavirus COVID-19 IgG ELISA kit (Epitope Diagnostics, Inc., San Diego, CA) detects nucleocapsid protein using enzymelinked immuno-sorbent assay technology. Results are reported semi-quantitatively as positive, equivocal or negative.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!